123 related articles for article (PubMed ID: 16432449)
1. The new arms race against melanoma.
Lejeune FJ
Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
[No Abstract] [Full Text] [Related]
2. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
3. Cancer research. Melanoma drug vindicates targeted approach.
Garber K
Science; 2009 Dec; 326(5960):1619. PubMed ID: 20019269
[No Abstract] [Full Text] [Related]
4. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
6. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
Gutzmer R
J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
[No Abstract] [Full Text] [Related]
7. Fisetin: a natural fist against melanoma?
Arbiser JL; Fisher DE
J Invest Dermatol; 2011 Jun; 131(6):1187-9. PubMed ID: 21566577
[TBL] [Abstract][Full Text] [Related]
8. Is B-Raf a good therapeutic target for melanoma and other malignancies?
Madhunapantula SV; Robertson GP
Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
Alcalá AM; Flaherty KT
Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
[TBL] [Abstract][Full Text] [Related]
10. The brothers RAF.
Kwong LN; Chin L
Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832
[TBL] [Abstract][Full Text] [Related]
11. [Gene abnormalities in melanoma and signal transduction antagonists].
Takada M
Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
[No Abstract] [Full Text] [Related]
12. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma: molecular cytogenetics and their implications in clinical medicine.
Junkins-Hopkins JM
J Am Acad Dermatol; 2010 Aug; 63(2):329-32. PubMed ID: 20633801
[No Abstract] [Full Text] [Related]
14. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
Verduzco D; Flaherty KT; Smalley KS
Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
[No Abstract] [Full Text] [Related]
15. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
16. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
17. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
18. Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Melnikova VO; Bar-Eli M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130
[No Abstract] [Full Text] [Related]
19. New therapeutic options in the medical management of advanced melanoma.
Lutzky J
Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538
[TBL] [Abstract][Full Text] [Related]
20. Targeting growth factors and angiogenesis; using small molecules in malignancy.
Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
